Definitive Contract 75A50120C00180
Award Date
9/29/20
Potential Completion Date
12/30/26
Potential Value
$29M
Awardee
Vaxxas PTY LTD
Ultimate Awardee
The University Of Queensland
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Australia
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...
This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Sanofi Pasteur Biologics, LLC for the production and testing of a Modified Vaccinia Ankara (MVA) vaccine. The contract award has a ceiling value of $74,940,566.62 and an ultimate completion date of February 6, 2015. The contract is not designated as a set-aside. As a child company of the Sanofi group, Sanofi...
This is a $35,019,405.00 firm fixed-price delivery order contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Seqirus Inc., a foreign-owned, for-profit biotechnology company that specializes in pandemic preparedness and response. The purpose of the contract is to procure an influenza A(H2Nx) virus vaccine candidate(s) and conduct related clinical trials. This order is part of a larger $13.4 billion...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Sanofi Pasteur Biologics, LLC, a foreign-owned for-profit organization. The contract is for the development and testing of a modified vaccinia Ankara (MVA) vaccine, with a ceiling value of $12,667,339.96. The contract is a definitive, cost-plus-fixed-fee contract type, with a final completion date of January 8, 2007. The...
The federal contract award HHSN272200800039C was a $8,394,390.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Vaxine PTY LTD, a for-profit organization, on September 30, 2008. The contract is part of NIAID's Adjuvant Discovery Program and is for biomedical research services. It has a cost-no-fee pricing type and an ultimate completion date of September 29, 2013. The contract was not set aside for any specific business...
This federal contract award, identified as 75A50118P00012, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The $42,247 firm fixed-price purchase order was awarded to Seqirus Inc., a foreign-owned, for-profit manufacturer of medical countermeasures, vaccines, and related products. The contract has no set-aside designation and was issued under Seqirus' $13.4 billion Indefinite...
This is a $16,382,387.80 cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to PPD Development, LP. The contract is for clinical services described in Tasks 1 through 15 under the ASPR-16-05933 requirement, which is part of the Medical Countermeasures Clinical Studies Network IDIQ contract vehicle. The contract is for a Heterologous Prime Boost Influenza Vaccine Trial and does not have a set-aside...
This is a definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AlphaVax Human Vaccines Inc. for R&D in physical science and exploratory development. The contract has a ceiling value of $16,660,130.44 and an ultimate completion date of August 14, 2012. It was initially awarded on September 26, 2003 and does not have a set-aside designation. AlphaVax Human Vaccines Inc. is a for-profit organization that...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...
<p>This is a Cost Plus Fixed Fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Altimmune, Inc. for the development of a single-dose intranasal vaccine for post-exposure prophylaxis of inhalation anthrax. The award has a ceiling value of $135,880,962.00 and a period of performance through December 31, 2021. The contract was awarded on July 27, 2016 and does not have a set-aside designation.</p>